Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + portal vein tumor thrombus seed implantation + lenvatinib in HCC with portal vein tumor thrombus
ChiCTR2200059078Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), sponsored by Henan Cancer Hospital. Primary endpoint: Time to progression. Planned start May 2022; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on ChiCTR2200059078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059078.